{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T03:23:30Z","timestamp":1777087410641,"version":"3.51.4"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T00:00:00Z","timestamp":1744934400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T00:00:00Z","timestamp":1744934400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100020581","name":"Fondazione AIRC per la ricerca sul cancro ETS","doi-asserted-by":"publisher","award":["26002"],"award-info":[{"award-number":["26002"]}],"id":[{"id":"10.13039\/100020581","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["PRIN2022 (2022T3ZALK)"],"award-info":[{"award-number":["PRIN2022 (2022T3ZALK)"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007195","name":"Universit\u00e0 degli Studi di Napoli Federico II","doi-asserted-by":"publisher","award":["FRA 2020-Linea B"],"award-info":[{"award-number":["FRA 2020-Linea B"]}],"id":[{"id":"10.13039\/100007195","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Mol Biol Lett"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Prostate cancer (PCa) is the second most common cancer affecting men globally, especially those aged 50\u00a0years and above. Despite substantial progress in terms of both prognosis and therapy, PCa remains a significant health concern, necessitating the identification of novel therapeutic targets. Innate lymphoid cells (ILCs) have emerged as critical modulators of tumor immunity, exhibiting both pro- and antitumoral effects. However, little is known yet about their contribution in PCa. This study investigated the phenotypic and functional profiles of ILC subsets in the peripheral blood mononuclear cells (PBMCs) of patients with PCa stratified by Gleason score.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>PBMCs were isolated by Lymphoprep. ILC frequency and activity were evaluated by flow cytometry. The levels of ILC-activating cytokines were analyzed by multiplex assay in the serum of healthy donors (HDs) and patients with PCa. To evaluate the crosstalk between ILC2s and cancer cells, PC3 and DU145 human PCa cell lines were used.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>We found a stage-dependent increase in the protumoral ILC2 frequency and a concurrent decrease in antitumoral ILC1s in patients with PCa compared with healthy controls. Interestingly, the frequency of ILC2s was higher in patients with elevated prostate-specific antigen (PSA) values, suggesting their potential as molecular predictor for defining the risk category of patients with PCa at diagnosis. Importantly, patients with PCa exhibited hyperactivated ILC2s, characterized by elevated interleukin (IL)-13 and IL-5 production, while ILC1s displayed reduced tumor necrosis factor (TNF)-\u03b1 and interferon (IFN)-\u03b3 secretion. Furthermore, serum levels of ILC2-activating cytokines IL-33, IL-18, and prostaglandin D2 (PGD2) were elevated in patients with PCa. In vitro co-culture experiments demonstrated that PCa cell lines, capable of secreting these cytokines, could directly enhance ILC2 activity. Likewise, ILC2-derived IL-13 promoted PCa cell migration and invasion.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Collectively, our findings highlight a dysregulated ILC profile in PCa, characterized by ILC2 dominance and heightened activity at the expense of ILC1s, suggesting both ILC1s and ILC2s as potential therapeutic targets for PCa treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Graphical Abstract<\/jats:title>\n          <\/jats:sec>","DOI":"10.1186\/s11658-025-00725-7","type":"journal-article","created":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T02:57:16Z","timestamp":1744945036000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Circulating innate lymphoid cells are dysregulated in patients with prostate cancer"],"prefix":"10.1186","volume":"30","author":[{"given":"Daniela Claudia","family":"Maresca","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evelina","family":"La Civita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedetta","family":"Romano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Rosaria","family":"Ambrosio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Somma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tania","family":"Wyss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernardo","family":"Rocco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Rubino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Cari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Krebs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Rodriguez-Calero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Ferro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Trabanelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camilla","family":"Jandus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felice","family":"Crocetto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Ianaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Terracciano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6026-2588","authenticated-orcid":false,"given":"Giuseppe","family":"Ercolano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,18]]},"reference":[{"key":"725_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"725_CR2","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1056\/NEJM198710083171501","volume":"317","author":"TA Stamey","year":"1987","unstructured":"Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987;317:909\u201316.","journal-title":"N Engl J Med"},{"key":"725_CR3","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1016\/S0022-5347(17)32300-5","volume":"152","author":"WJ Catalona","year":"1994","unstructured":"Catalona WJ, Hudson MA, Scardino PT, Richie JP, Ahmann FR, Flanigan RC, et al. Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves. J Urol. 1994;152:2037\u201342.","journal-title":"J Urol"},{"key":"725_CR4","doi-asserted-by":"publisher","first-page":"5225","DOI":"10.2147\/CMAR.S250829","volume":"12","author":"CJ McNally","year":"2020","unstructured":"McNally CJ, Ruddock MW, Moore T, McKenna DJ. Biomarkers that differentiate benign prostatic hyperplasia from prostate cancer: a literature review. Cancer Manag Res. 2020;12:5225\u201341.","journal-title":"Cancer Manag Res"},{"key":"725_CR5","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/0090-4295(89)90131-3","volume":"33","author":"DL Dalton","year":"1989","unstructured":"Dalton DL. Elevated serum prostate-specific antigen due to acute bacterial prostatitis. Urology. 1989;33:465.","journal-title":"Urology"},{"key":"725_CR6","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1590\/S1677-5538.IBJU.2015.0116","volume":"42","author":"F Tarhan","year":"2016","unstructured":"Tarhan F, Demir K, Orcun A, Madenci OC. Effect of ejaculation on serum prostate-specific antigen concentration. Int Braz J Urol. 2016;42:472\u20138.","journal-title":"Int Braz J Urol"},{"key":"725_CR7","doi-asserted-by":"publisher","first-page":"e245","DOI":"10.1515\/cclm-2016-0018","volume":"54","author":"EP Diamandis","year":"2016","unstructured":"Diamandis EP. Significant increase of serum prostate-specific antigen after exercise. Clin Chem Lab Med. 2016;54:e245-246.","journal-title":"Clin Chem Lab Med"},{"key":"725_CR8","doi-asserted-by":"publisher","first-page":"442","DOI":"10.23736\/S2724-6051.21.04098-4","volume":"73","author":"M Ferro","year":"2021","unstructured":"Ferro M, Lucarelli G, de Cobelli O, Del Giudice F, Musi G, Mistretta FA, et al. The emerging landscape of tumor marker panels for the identification of aggressive prostate cancer: the perspective through bibliometric analysis of an Italian translational working group in uro-oncology. Minerva Urol Nephrol. 2021;73:442\u201351.","journal-title":"Minerva Urol Nephrol"},{"key":"725_CR9","unstructured":"David MK, Leslie SW. Prostate Specific Antigen. StatPearls. Treasure Island (FL): StatPearls Publishing; 2024. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK557495\/. Accessed 23 Apr 2024."},{"key":"725_CR10","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/S0022-5347(17)59889-4","volume":"111","author":"DF Gleason","year":"1974","unstructured":"Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol. 1974;111:58\u201364.","journal-title":"J Urol"},{"key":"725_CR11","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s11912-017-0568-7","volume":"19","author":"M Nakazawa","year":"2017","unstructured":"Nakazawa M, Paller C, Kyprianou N. Mechanisms of therapeutic resistance in prostate cancer. Curr Oncol Rep. 2017;19:13.","journal-title":"Curr Oncol Rep"},{"key":"725_CR12","doi-asserted-by":"publisher","first-page":"2801","DOI":"10.3389\/fimmu.2019.02801","volume":"10","author":"G Ercolano","year":"2019","unstructured":"Ercolano G, Falquet M, Vanoni G, Trabanelli S, Jandus C. ILC2s: new actors in tumor immunity. Front Immunol. 2019;10:2801.","journal-title":"Front Immunol"},{"key":"725_CR13","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/s41422-020-0326-5","volume":"30","author":"M Ghaedi","year":"2020","unstructured":"Ghaedi M, Ohashi PS. ILC transdifferentiation: roles in cancer progression. Cell Res. 2020;30:562\u20133.","journal-title":"Cell Res"},{"key":"725_CR14","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/s41590-022-01127-z","volume":"23","author":"N Jacquelot","year":"2022","unstructured":"Jacquelot N, Seillet C, Vivier E, Belz GT. Innate lymphoid cells and cancer. Nat Immunol. 2022;23:371\u20139.","journal-title":"Nat Immunol"},{"key":"725_CR15","doi-asserted-by":"publisher","first-page":"101276","DOI":"10.1016\/j.smim.2019.04.004","volume":"41","author":"S Trabanelli","year":"2019","unstructured":"Trabanelli S, Chevalier MF, Derr\u00e9 L, Jandus C. The pro- and anti-tumor role of ILC2s. Semin Immunol. 2019;41:101276.","journal-title":"Semin Immunol"},{"key":"725_CR16","first-page":"2396","volume":"108","author":"B Fiordi","year":"2023","unstructured":"Fiordi B, Salvestrini V, Gugliotta G, Castagnetti F, Curti A, Speiser DE, et al. IL-18 and VEGF-A trigger type 2 innate lymphoid cell accumulation and pro-tumoral function in chronic myeloid leukemia. Haematologica. 2023;108:2396\u2013409.","journal-title":"Haematologica"},{"key":"725_CR17","doi-asserted-by":"publisher","first-page":"eabn0175","DOI":"10.1126\/sciimmunol.abn0175","volume":"7","author":"E Jou","year":"2022","unstructured":"Jou E, Rodriguez-Rodriguez N, Ferreira A-CF, Jolin HE, Clark PA, Sawmynaden K, et al. An innate IL-25-ILC2-MDSC axis creates a cancer-permissive microenvironment for Apc mutation-driven intestinal tumorigenesis. Sci Immunol. 2022;7:eabn0175.","journal-title":"Sci Immunol"},{"key":"725_CR18","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1080\/08830185.2023.2247021","volume":"43","author":"R Roy","year":"2024","unstructured":"Roy R, Das T, Biswas N. Orchestration of immune response by innate lymphoid cell subtype 2 at various tumor microenvironment, a suitable target for cancer immunotherapy. Int Rev Immunol. 2024;43:74\u201382.","journal-title":"Int Rev Immunol"},{"key":"725_CR19","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/s41586-020-2015-4","volume":"579","author":"JA Moral","year":"2020","unstructured":"Moral JA, Leung J, Rojas LA, Ruan J, Zhao J, Sethna Z, et al. ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity. Nature. 2020;579:130\u20135.","journal-title":"Nature"},{"key":"725_CR20","doi-asserted-by":"publisher","first-page":"296","DOI":"10.37349\/etat.2024.00219","volume":"5","author":"JM Verner","year":"2024","unstructured":"Verner JM, Arbuthnott HF, Ramachandran R, Bharadwaj M, Chaudhury N, Jou E. Emerging roles of type 1 innate lymphoid cells in tumour pathogenesis and cancer immunotherapy. Explor Target Antitumor Ther. 2024;5:296\u2013315.","journal-title":"Explor Target Antitumor Ther"},{"key":"725_CR21","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/BF00195979","volume":"14","author":"K Dawe","year":"1993","unstructured":"Dawe K, Hutchings P, Champion B, Cooke A, Roitt I. Autoantigens in thyroid diseases. Springer Semin Immunopathol. 1993;14:285\u2013307.","journal-title":"Springer Semin Immunopathol"},{"key":"725_CR22","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1158\/2326-6066.CIR-19-0504","volume":"8","author":"G Ercolano","year":"2020","unstructured":"Ercolano G, Garcia-Garijo A, Salom\u00e9 B, Gomez-Cadena A, Vanoni G, Mastelic-Gavillet B, et al. Immunosuppressive mediators impair proinflammatory innate lymphoid cell function in human malignant melanoma. Cancer Immunol Res. 2020;8:556\u201364.","journal-title":"Cancer Immunol Res"},{"key":"725_CR23","doi-asserted-by":"publisher","first-page":"3674","DOI":"10.1182\/bloodadvances.2018030478","volume":"3","author":"B Salom\u00e9","year":"2019","unstructured":"Salom\u00e9 B, Gomez-Cadena A, Loyon R, Suffiotti M, Salvestrini V, Wyss T, et al. CD56 as a marker of an ILC1-like population with NK cell properties that is functionally impaired in AML. Blood Adv. 2019;3:3674\u201387.","journal-title":"Blood Adv"},{"key":"725_CR24","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/j.cell.2017.02.021","volume":"168","author":"AI Lim","year":"2017","unstructured":"Lim AI, Li Y, Lopez-Lastra S, Stadhouders R, Paul F, Casrouge A, et al. Systemic human ILC precursors provide a substrate for tissue ILC differentiation. Cell. 2017;168:1086-1100.e10.","journal-title":"Cell"},{"key":"725_CR25","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.17278","author":"V Papa","year":"2024","unstructured":"Papa V, Li Pomi F, Borgia F, Vaccaro M, Pioggia G, Gangemi S. Alarmins in cutaneous malignant melanoma: an updated overview of emerging evidence on their pathogenetic, diagnostic, prognostic, and therapeutic role. J Dermatol. 2024. https:\/\/doi.org\/10.1111\/1346-8138.17278.","journal-title":"J Dermatol"},{"key":"725_CR26","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/s00262-024-03676-8","volume":"73","author":"G Perri","year":"2024","unstructured":"Perri G, Vilas Boas VG, Nogueira MRS, Mello J\u00fanior EJF, Coelho AL, Posadas EM, et al. Interleukin 33 supports squamous cell carcinoma growth via a dual effect on tumour proliferation, migration and invasion, and T cell activation. Cancer Immunol Immunother. 2024;73:110.","journal-title":"Cancer Immunol Immunother"},{"key":"725_CR27","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1016\/j.jaci.2022.07.003","volume":"150","author":"AG Stanbery","year":"2022","unstructured":"Stanbery AG, Smita S, von Moltke J, Tait Wojno ED, Ziegler SF. TSLP, IL-33, and IL-25: not just for allergy and helminth infection. J Allergy Clin Immunol. 2022;150:1302\u201313.","journal-title":"J Allergy Clin Immunol"},{"key":"725_CR28","doi-asserted-by":"publisher","first-page":"1244437","DOI":"10.3389\/fimmu.2023.1244437","volume":"14","author":"I Bahhar","year":"2023","unstructured":"Bahhar I, E\u015f Z, K\u00f6se O, Turna A, G\u00fcnl\u00fco\u011flu MZ, \u00c7ak\u0131r A, et al. The IL-25\/ILC2 axis promotes lung cancer with a concomitant accumulation of immune-suppressive cells in tumors in humans and mice. Front Immunol. 2023;14:1244437.","journal-title":"Front Immunol"},{"key":"725_CR29","doi-asserted-by":"publisher","first-page":"7101","DOI":"10.1002\/cam4.4243","volume":"10","author":"N Mukherjee","year":"2021","unstructured":"Mukherjee N, Ji N, Tan X, Lin C-L, Rios E, Chen C-L, et al. Bladder tumor ILC1s undergo Th17-like differentiation in human bladder cancer. Cancer Med. 2021;10:7101\u201310.","journal-title":"Cancer Med"},{"key":"725_CR30","doi-asserted-by":"publisher","first-page":"2916","DOI":"10.1172\/JCI89717","volume":"127","author":"MF Chevalier","year":"2017","unstructured":"Chevalier MF, Trabanelli S, Racle J, Salom\u00e9 B, Cesson V, Gharbi D, et al. ILC2-modulated T cell-to-MDSC balance is associated with bladder cancer recurrence. J Clin Invest. 2017;127:2916\u201329.","journal-title":"J Clin Invest"},{"key":"725_CR31","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/s41467-017-00678-2","volume":"8","author":"S Trabanelli","year":"2017","unstructured":"Trabanelli S, Chevalier MF, Martinez-Usatorre A, Gomez-Cadena A, Salom\u00e9 B, Lecciso M, et al. Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis. Nat Commun. 2017;8:593.","journal-title":"Nat Commun"},{"key":"725_CR32","doi-asserted-by":"publisher","first-page":"559","DOI":"10.3390\/cancers13030559","volume":"13","author":"Q Huang","year":"2021","unstructured":"Huang Q, Jacquelot N, Preaudet A, Hediyeh-Zadeh S, Souza-Fonseca-Guimaraes F, McKenzie ANJ, et al. Type 2 innate lymphoid cells protect against colorectal cancer progression and predict improved patient survival. Cancers. 2021;13:559.","journal-title":"Cancers"},{"key":"725_CR33","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv1507","volume":"44","author":"A Colaprico","year":"2016","unstructured":"Colaprico A, Silva TC, Olsen C, Garofano L, Cava C, Garolini D, et al. TCGAbiolinks: an R\/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res. 2016;44: e71.","journal-title":"Nucleic Acids Res"},{"key":"725_CR34","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43: e47.","journal-title":"Nucleic Acids Res"},{"key":"725_CR35","first-page":"2091","volume":"16","author":"J Chu","year":"2018","unstructured":"Chu J, Li N, Li F. A risk score staging system based on the expression of seven genes predicts the outcome of bladder cancer. Oncol Lett. 2018;16:2091\u20136.","journal-title":"Oncol Lett"},{"key":"725_CR36","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/s41467-023-36325-2","volume":"14","author":"T Hirz","year":"2023","unstructured":"Hirz T, Mei S, Sarkar H, Kfoury Y, Wu S, Verhoeven BM, et al. Dissecting the immune suppressive human prostate tumor microenvironment via integrated single-cell and spatial transcriptomic analyses. Nat Commun. 2023;14:663.","journal-title":"Nat Commun"},{"key":"725_CR37","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.3390\/cancers14133267","volume":"14","author":"A Ito","year":"2022","unstructured":"Ito A, Akama Y, Satoh-Takayama N, Saito K, Kato T, Kawamoto E, et al. Possible metastatic stage-dependent ILC2 activation induces differential functions of MDSCs through IL-13\/IL-13R\u03b11 signaling during the progression of breast cancer lung metastasis. Cancers. 2022;14:3267.","journal-title":"Cancers"},{"key":"725_CR38","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1002\/eji.202049033","volume":"51","author":"X Yuan","year":"2021","unstructured":"Yuan X, Rasul F, Nashan B, Sun C. Innate lymphoid cells and cancer: Role in tumor progression and inhibition. Eur J Immunol. 2021;51:2188\u2013205.","journal-title":"Eur J Immunol"},{"key":"725_CR39","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.1038\/s41467-021-22764-2","volume":"12","author":"G Ercolano","year":"2021","unstructured":"Ercolano G, Gomez-Cadena A, Dumauthioz N, Vanoni G, Kreutzfeldt M, Wyss T, et al. PPAR\u03b3 drives IL-33-dependent ILC2 pro-tumoral functions. Nat Commun. 2021;12:2538.","journal-title":"Nat Commun"},{"key":"725_CR40","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s41577-020-0282-9","volume":"20","author":"SM Bal","year":"2020","unstructured":"Bal SM, Golebski K, Spits H. Plasticity of innate lymphoid cell subsets. Nat Rev Immunol. 2020;20:552\u201365.","journal-title":"Nat Rev Immunol"},{"key":"725_CR41","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/imr.13327","volume":"323","author":"R Sudan","year":"2024","unstructured":"Sudan R, Gilfillan S, Colonna M. Group 1 ILCs: heterogeneity, plasticity, and transcriptional regulation. Immunol Rev. 2024;323:107\u201317.","journal-title":"Immunol Rev"},{"key":"725_CR42","doi-asserted-by":"publisher","first-page":"3570","DOI":"10.3390\/cancers13143570","volume":"13","author":"S Occhipinti","year":"2021","unstructured":"Occhipinti S, Mengozzi G, Oderda M, Zitella A, Molinaro L, Novelli F, et al. Low levels of urinary PSA better identify prostate cancer patients. Cancers. 2021;13:3570.","journal-title":"Cancers"},{"key":"725_CR43","doi-asserted-by":"publisher","first-page":"620","DOI":"10.6004\/jnccn.2018.0036","volume":"16","author":"PH Carroll","year":"2018","unstructured":"Carroll PH, Mohler JL. NCCN guidelines updates: prostate cancer and prostate cancer early detection. J Natl Compr Canc Netw. 2018;16:620\u20133.","journal-title":"J Natl Compr Canc Netw"},{"key":"725_CR44","doi-asserted-by":"publisher","first-page":"300060521105315","DOI":"10.1177\/03000605211053156","volume":"50","author":"J Jin","year":"2022","unstructured":"Jin J, Sunusi S, Lu H. Group 2 innate lymphoid cells (ILC2s) are important in typical type 2 immune-mediated diseases and an essential therapeutic target. J Int Med Res. 2022;50:3000605211053156.","journal-title":"J Int Med Res"},{"key":"725_CR45","doi-asserted-by":"publisher","first-page":"14026","DOI":"10.3390\/ijms241814026","volume":"24","author":"B Stojanovic","year":"2023","unstructured":"Stojanovic B, Gajovic N, Jurisevic M, Stojanovic MD, Jovanovic M, Jovanovic I, et al. Decoding the IL-33\/ST2 Axis: its impact on the immune landscape of breast cancer. Int J Mol Sci. 2023;24:14026.","journal-title":"Int J Mol Sci"},{"key":"725_CR46","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1002\/eji.202149175","volume":"51","author":"W Jiang","year":"2021","unstructured":"Jiang W, Lian J, Yue Y, Zhang Y. IL-33\/ST2 as a potential target for tumor immunotherapy. Eur J Immunol. 2021;51:1943\u201355.","journal-title":"Eur J Immunol"},{"key":"725_CR47","first-page":"6439614","volume":"2020","author":"X Feng","year":"2020","unstructured":"Feng X, Zhang Z, Sun P, Song G, Wang L, Sun Z, et al. Interleukin-18 Is a prognostic marker and plays a tumor suppressive role in colon cancer. Dis Mark. 2020;2020:6439614.","journal-title":"Dis Mark"},{"key":"725_CR48","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1158\/0008-5472.CAN-17-0307","volume":"77","author":"T Li","year":"2017","unstructured":"Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77:e108\u201310.","journal-title":"Cancer Res"},{"key":"725_CR49","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202302175","volume":"10","author":"T Wu","year":"2023","unstructured":"Wu T, Tan JHL, Sin W-X, Luah YH, Tan SY, Goh M, et al. Cell granularity reflects immune cell function and enables selection of lymphocytes with superior attributes for immunotherapy. Adv Sci. 2023;10: e2302175.","journal-title":"Adv Sci"},{"key":"725_CR50","doi-asserted-by":"publisher","first-page":"61183","DOI":"10.18632\/oncotarget.11282","volume":"7","author":"H Cao","year":"2016","unstructured":"Cao H, Zhang J, Liu H, Wan L, Zhang H, Huang Q, et al. IL-13\/STAT6 signaling plays a critical role in the epithelial-mesenchymal transition of colorectal cancer cells. Oncotarget. 2016;7:61183\u201398.","journal-title":"Oncotarget"},{"key":"725_CR51","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.3390\/ijms22062998","volume":"22","author":"J Shi","year":"2021","unstructured":"Shi J, Song X, Traub B, Luxenhofer M, Kornmann M. Involvement of IL-4, IL-13 and their receptors in pancreatic cancer. Int J Mol Sci. 2021;22:2998.","journal-title":"Int J Mol Sci"},{"key":"725_CR52","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1038\/s41419-023-06255-4","volume":"14","author":"RA Bartolom\u00e9","year":"2023","unstructured":"Bartolom\u00e9 RA, Mart\u00edn-Regalado \u00c1, Pintado-Berninches L, Robles J, Ram\u00edrez-Gonz\u00e1lez M\u00c1, Boukich I, et al. Schnurri-3 drives tumor growth and invasion in cancer cells expressing interleukin-13 receptor alpha 2. Cell Death Dis. 2023;14:742.","journal-title":"Cell Death Dis"},{"key":"725_CR53","doi-asserted-by":"publisher","first-page":"878365","DOI":"10.3389\/fimmu.2022.878365","volume":"13","author":"KM Knudson","year":"2022","unstructured":"Knudson KM, Hwang S, McCann MS, Joshi BH, Husain SR, Puri RK. Recent advances in IL-13R\u03b12-directed cancer immunotherapy. Front Immunol. 2022;13:878365.","journal-title":"Front Immunol"},{"key":"725_CR54","doi-asserted-by":"publisher","first-page":"W556","DOI":"10.1093\/nar\/gkz430","volume":"47","author":"Z Tang","year":"2019","unstructured":"Tang Z, Kang B, Li C, Chen T, Zhang Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 2019;47:W556\u201360.","journal-title":"Nucleic Acids Res"},{"key":"725_CR55","doi-asserted-by":"publisher","first-page":"675","DOI":"10.3390\/cells8070675","volume":"8","author":"M Xia","year":"2019","unstructured":"Xia M, Liu C-J, Zhang Q, Guo A-Y. GEDS: a gene expression display server for mRNAs, miRNAs and proteins. Cells. 2019;8:675.","journal-title":"Cells"},{"key":"725_CR56","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.immuni.2017.09.015","volume":"47","author":"M Osbourn","year":"2017","unstructured":"Osbourn M, Soares DC, Vacca F, Cohen ES, Scott IC, Gregory WF, et al. HpARI protein secreted by a helminth parasite suppresses interleukin-33. Immunity. 2017;47:739-751.e5.","journal-title":"Immunity"},{"key":"725_CR57","doi-asserted-by":"publisher","first-page":"5539","DOI":"10.1038\/s41598-018-23847-9","volume":"8","author":"AR Lima","year":"2018","unstructured":"Lima AR, Ara\u00fajo AM, Pinto J, Jer\u00f3nimo C, Henrique R, de Bastos ML, et al. Discrimination between the human prostate normal and cancer cell exometabolome by GC-MS. Sci Rep. 2018;8:5539.","journal-title":"Sci Rep"},{"key":"725_CR58","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s00262-003-0445-0","volume":"53","author":"M Terabe","year":"2004","unstructured":"Terabe M, Park JM, Berzofsky JA. Role of IL-13 in regulation of anti-tumor immunity and tumor growth. Cancer Immunol Immunother. 2004;53:79\u201385.","journal-title":"Cancer Immunol Immunother"},{"key":"725_CR59","doi-asserted-by":"publisher","first-page":"211.27","DOI":"10.4049\/jimmunol.194.Supp.211.27","volume":"194","author":"D Gurusamy","year":"2015","unstructured":"Gurusamy D, Shoe J, Hocker J, Hurwitz A. A role for IL-13 in the progression of prostate tumors (TUM10P.1046). J Immunol. 2015;194:211.27-211.27.","journal-title":"J Immunol"},{"key":"725_CR60","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/S0022-5347(01)64369-6","volume":"158","author":"A Maini","year":"1997","unstructured":"Maini A, Hillman G, Haas GP, Wang CY, Montecillo E, Hamzavi F, et al. Interleukin-13 receptors on human prostate carcinoma cell lines represent a novel target for a chimeric protein composed of IL-13 and a mutated form of Pseudomonas exotoxin. J Urol. 1997;158:948\u201353.","journal-title":"J Urol"},{"key":"725_CR61","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1002\/ijc.20789","volume":"114","author":"O Gonzalez-Moreno","year":"2005","unstructured":"Gonzalez-Moreno O, Calvo A, Joshi BH, Abasolo I, Leland P, Wang Z, et al. Gene expression profiling identifies IL-13 receptor alpha 2 chain as a therapeutic target in prostate tumor cells overexpressing adrenomedullin. Int J Cancer. 2005;114:870\u20138.","journal-title":"Int J Cancer"},{"key":"725_CR62","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s10911-010-9177-x","volume":"15","author":"ES Radisky","year":"2010","unstructured":"Radisky ES, Radisky DC. Matrix metalloproteinase-induced epithelial-mesenchymal transition in breast cancer. J Mammary Gland Biol Neoplasia. 2010;15:201\u201312.","journal-title":"J Mammary Gland Biol Neoplasia"},{"key":"725_CR63","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.urolonc.2024.05.002","volume":"42","author":"S Zhu","year":"2024","unstructured":"Zhu S, He J, Yin L, Zhou J, Lian J, Ren Y, et al. Matrix metalloproteinases targeting in prostate cancer. Urol Oncol. 2024;42:275\u201387.","journal-title":"Urol Oncol"},{"key":"725_CR64","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.3390\/cancers15082309","volume":"15","author":"S Gogola","year":"2023","unstructured":"Gogola S, Rejzer M, Bahmad HF, Abou-Kheir W, Omarzai Y, Poppiti R. Epithelial-to-mesenchymal transition-related markers in prostate cancer: from bench to bedside. Cancers. 2023;15:2309.","journal-title":"Cancers"},{"key":"725_CR65","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3389\/fimmu.2019.00171","volume":"10","author":"C B\u00e9n\u00e9zech","year":"2019","unstructured":"B\u00e9n\u00e9zech C, Jackson-Jones LH. ILC2 orchestration of local immune function in adipose tissue. Front Immunol. 2019;10:171.","journal-title":"Front Immunol"},{"key":"725_CR66","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1093\/cei\/uxad050","volume":"213","author":"ML Mak","year":"2023","unstructured":"Mak ML, Reid KT, Crome SQ. Protective and pathogenic functions of innate lymphoid cells in transplantation. Clin Exp Immunol. 2023;213:23\u201339.","journal-title":"Clin Exp Immunol"},{"key":"725_CR67","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1038\/s41590-021-00943-z","volume":"22","author":"N Jacquelot","year":"2021","unstructured":"Jacquelot N, Seillet C, Wang M, Pizzolla A, Liao Y, Hediyeh-Zadeh S, et al. Blockade of the co-inhibitory molecule PD-1 unleashes ILC2-dependent antitumor immunity in melanoma. Nat Immunol. 2021;22:851\u201364.","journal-title":"Nat Immunol"},{"key":"725_CR68","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1038\/s41423-022-00901-1","volume":"19","author":"S Curio","year":"2022","unstructured":"Curio S, Belz GT. The unique role of innate lymphoid cells in cancer and the hepatic microenvironment. Cell Mol Immunol. 2022;19:1012\u201329.","journal-title":"Cell Mol Immunol"},{"key":"725_CR69","doi-asserted-by":"publisher","first-page":"e257","DOI":"10.3324\/haematol.2014.119602","volume":"100","author":"S Trabanelli","year":"2015","unstructured":"Trabanelli S, Curti A, Lecciso M, Salom\u00e9 B, Riether C, Ochsenbein A, et al. CD127+ innate lymphoid cells are dysregulated in treatment na\u00efve acute myeloid leukemia patients at diagnosis. Haematologica. 2015;100:e257-260.","journal-title":"Haematologica"},{"key":"725_CR70","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13062-023-00401-w","volume":"18","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Ma S, Li T, Tian Y, Zhou H, Wang H, et al. ILC1-derived IFN-\u03b3 regulates macrophage activation in colon cancer. Biol Direct. 2023;18:56.","journal-title":"Biol Direct"},{"key":"725_CR71","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1089\/jir.2024.0008","volume":"44","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Zhu K, Wang X, Zhao Y, Shi J, Liu Z. Roles of IL-4, IL-13, and their receptors in lung cancer. J Interferon Cytokine Res. 2024;44:399\u2013407.","journal-title":"J Interferon Cytokine Res"},{"key":"725_CR72","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1084\/jem.20161807","volume":"214","author":"S Laffont","year":"2017","unstructured":"Laffont S, Blanquart E, Savignac M, C\u00e9nac C, Laverny G, Metzger D, et al. Androgen signaling negatively controls group 2 innate lymphoid cells. J Exp Med. 2017;214:1581\u201392.","journal-title":"J Exp Med"},{"key":"725_CR73","volume":"18","author":"L Hua","year":"2020","unstructured":"Hua L, Xia H, Zheng W. The association between immune infiltration and clinical phenotypes and prognosis of prostate cancer. Iran J Biotechnol. 2020;18: e2538.","journal-title":"Iran J Biotechnol"},{"key":"725_CR74","doi-asserted-by":"publisher","first-page":"3028","DOI":"10.1038\/s41375-020-0843-8","volume":"34","author":"L Wu","year":"2020","unstructured":"Wu L, Lin Q, Ma Z, Chowdhury FA, Mazumder MHH, Du W. Mesenchymal PGD2 activates an ILC2-Treg axis to promote proliferation of normal and malignant HSPCs. Leukemia. 2020;34:3028\u201341.","journal-title":"Leukemia"},{"key":"725_CR75","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1056\/NEJMoa2209454","volume":"387","author":"J Hugosson","year":"2022","unstructured":"Hugosson J, M\u00e5nsson M, Wallstr\u00f6m J, Axcrona U, Carlsson SV, Egevad L, et al. Prostate cancer screening with PSA and MRI followed by targeted biopsy only. N Engl J Med. 2022;387:2126\u201337.","journal-title":"N Engl J Med"},{"key":"725_CR76","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.3389\/fimmu.2019.02121","volume":"10","author":"R Loyon","year":"2019","unstructured":"Loyon R, Jary M, Salom\u00e9 B, Gomez-Cadena A, Galaine J, Kroemer M, et al. Peripheral innate lymphoid cells are increased in first line metastatic colorectal carcinoma patients: a negative correlation with Th1 immune responses. Front Immunol. 2019;10:2121.","journal-title":"Front Immunol"},{"key":"725_CR77","doi-asserted-by":"publisher","first-page":"155961","DOI":"10.1016\/j.cyto.2022.155961","volume":"157","author":"WJ Yeoh","year":"2022","unstructured":"Yeoh WJ, Vu VP, Krebs P. IL-33 biology in cancer: an update and future perspectives. Cytokine. 2022;157:155961.","journal-title":"Cytokine"},{"key":"725_CR78","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/ni.3308","volume":"17","author":"CU Duerr","year":"2016","unstructured":"Duerr CU, McCarthy CDA, Mindt BC, Rubio M, Meli AP, Pothlichet J, et al. Type I interferon restricts type 2 immunopathology through the regulation of group 2 innate lymphoid cells. Nat Immunol. 2016;17:65\u201375.","journal-title":"Nat Immunol"},{"key":"725_CR79","doi-asserted-by":"publisher","first-page":"1146077","DOI":"10.3389\/fimmu.2023.1146077","volume":"14","author":"AA Korchagina","year":"2023","unstructured":"Korchagina AA, Shein SA, Koroleva E, Tumanov AV. Transcriptional control of ILC identity. Front Immunol. 2023;14:1146077.","journal-title":"Front Immunol"},{"key":"725_CR80","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/978-981-99-9781-7_8","volume":"1444","author":"K Ikuta","year":"2024","unstructured":"Ikuta K, Asahi T, Cui G, Abe S, Takami D. Control of the development, distribution, and function of innate-like lymphocytes and innate lymphoid cells by the tissue microenvironment. Adv Exp Med Biol. 2024;1444:111\u201327.","journal-title":"Adv Exp Med Biol"},{"key":"725_CR81","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1038\/s41467-019-09883-7","volume":"10","author":"K Golebski","year":"2019","unstructured":"Golebski K, Ros XR, Nagasawa M, van Tol S, Heesters BA, Aglmous H, et al. IL-1\u03b2, IL-23, and TGF-\u03b2 drive plasticity of human ILC2s towards IL-17-producing ILCs in nasal inflammation. Nat Commun. 2019;10:2162.","journal-title":"Nat Commun"},{"key":"725_CR82","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1038\/s41590-019-0423-0","volume":"20","author":"JH Bernink","year":"2019","unstructured":"Bernink JH, Ohne Y, Teunissen MBM, Wang J, Wu J, Krabbendam L, et al. c-Kit-positive ILC2s exhibit an ILC3-like signature that may contribute to IL-17-mediated pathologies. Nat Immunol. 2019;20:992\u20131003.","journal-title":"Nat Immunol"},{"key":"725_CR83","doi-asserted-by":"publisher","first-page":"356","DOI":"10.3390\/biom13020356","volume":"13","author":"R Jannoo","year":"2023","unstructured":"Jannoo R, Xia Z, Row PE, Kanamarlapudi V. Targeting of the interleukin-13 receptor (IL-13R)\u03b12 expressing prostate cancer by a novel hybrid lytic peptide. Biomolecules. 2023;13:356.","journal-title":"Biomolecules"}],"container-title":["Cellular &amp; Molecular Biology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s11658-025-00725-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s11658-025-00725-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s11658-025-00725-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T04:02:30Z","timestamp":1744948950000},"score":1,"resource":{"primary":{"URL":"https:\/\/cmbl.biomedcentral.com\/articles\/10.1186\/s11658-025-00725-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,18]]},"references-count":83,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["725"],"URL":"https:\/\/doi.org\/10.1186\/s11658-025-00725-7","relation":{},"ISSN":["1689-1392"],"issn-type":[{"value":"1689-1392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,18]]},"assertion":[{"value":"9 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Venous blood was drawn from HDs and patients with PCa at the University Hospital Federico II in Naples, between September 2021 and December 2023. This study was conducted in accordance with the Declaration of Helsinki (revised in 2013). The study protocol was approved by the Ethics Committee of the University Hospital Federico II in Naples (approval no. 180\/20). All participants provided informed consent before participating in the study. For IHC, human prostate tissues were provided by the Tissue Bank Bern. Analyses of the samples were approved by the Cantonal Ethics Committee of Bern (200\/2014 and 2024-02031).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no potential competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"48"}}